The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

发表于 3 小时前

期刊：Science Translational Medicine

文献作者：Seblewongel Asrat; Wei Keat Lim; Subhashini Srivatsan; Sivan Harel; Kaitlyn Gayvert; Dylan Birchard; Matthew F. Wipperman; Dave Singh; Andrea T. Hooper; George Scott; Julie E. Horowitz; Jonas S. Erjefalt; Caroline Sanden; Kirsten Nagashima; Brianna Buonagurio; Li-Hong Ben; Erica Chio; Audrey Le Floc’h; Jeanne Allinne; Jennifer Maloney; George D. Kalliolias; Marcella Ruddy; Sara C. Hamon; Gary A. Herman; Andrew J. Murphy; Helene Goulaouic; Matthew A. Sleeman; Jennifer D. Hamilton; Jamie M. Orengo

出版日期：2025-10-29

DOI号：10.1126/scitranslmed.adu3759

下载链接：https://www.science.org/doi/pdf/10.1126/scitranslmed.adu3759

文献链接：https://doi.org/10.1126/scitranslmed.adu3759

当前文献来源于 American Association for the Advancement of Science (AAAS)。

备注信息：

[AAAS] The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[AAAS] The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma 一键复制

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[AAAS] The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma